FORTRESS (Fosfomycin i.v. for treatment of severely infected patients)

• Research type

  Research Study

• Full title

  A European, multicentre, non-comparative, noninterventional,prospective clinical registry to evaluate the clinical outcome and safety of the treatment of severely infected patients with fosfomycin i.v.

• IRAS ID

  252005

• Contact name

  Abhijit M Bal

• Contact email

  abhijit.bal@nhs.net

• Sponsor organisation

  InfectoPharm Arzneimittel und Consilium GmbH

• Duration of Study in the UK

  1 years, 4 months, 13 days

• Research summary

  The antibiotic fosfomycin is considered to be a valuable agent for treatment of patients with high risk of resistant pathogens in initial empirical combination therapy, as targeted combination therapy in difficult to treat or deep seated infections or as rescue therapy in patients with multi-drug resistant pathogens. Fosfomycin has been used to treat serious bacterial infections in several European countries. For example bone infections, urinary tract infections, respiratory, tract infections, sepsis.

  In this study we will document data from participants with serious bacterial infections and look at the effectiveness and safety of fosfomycin.

• REC name

  Scotland A: Adults with Incapacity only

• REC reference

  18/SS/0130

• Date of REC Opinion

  30 Nov 2018

• REC opinion

  Further Information Favourable Opinion